MedTrace Logo

A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

NCT02154087 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2016-10-03

Study results available
· View outcomes & findings →

Summary

Assess the influence of HP802-247 on biochemical and cellular markers of inflammation in chronic venous leg ulcers

Conditions

  • Venous Leg Ulcers

Interventions

BIOLOGICAL

HP802-247

260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle

Sponsors & Collaborators

  • Healthpoint

    lead INDUSTRY

Principal Investigators

  • Herbert B Slade, MD · Smith & Nephew Biotherapeutics; Chief Medical Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-07-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02154087 on ClinicalTrials.gov